CAR-BCMA T cell therapy - CARsgen

Drug Profile

CAR-BCMA T cell therapy - CARsgen

Alternative Names: BCMA-redirected Autologous Cell

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CARsgen
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 26 Oct 2017 CARsgen plans a phase I trial for Myeloma in China (NCT03302403)
  • 05 Oct 2017 Preclinical trials in Multiple myeloma in China (IV-injection) before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top